Strides Arcolab receives its first injectable ANDA approval for Keterolac Tromethamine USP, 15mg/ml & 30 mg/ml

Strides Arcolab Ltd has announced that its first ANDA approval for Keterolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL.

The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn, Inc. (NASDAQ : AKRX) and the Company.

Ketrolac is the first approval amongst 22 sterile submissions the Company has submitted with US FDA and follows a successful FDA approval of its sterile manufacturing facility in India.

Arun Kumar - Vice Chairman and Managing Director of the Company stated "We are excited with our first sterile injectable approval and are delighted having achieved a key milestone in creating a global sterile injectable business".

The stock closed the day at Rs.320, down by Rs.0.85 or 0.26%. The stock hit an intraday high of Rs.326.95 and low of Rs.315. The total traded quantity was 4734 compared to 2 week average of 12288.

Source : Equity Bulls

Keywords